<DOC>
	<DOCNO>NCT00764634</DOCNO>
	<brief_summary>This Phase 2 study double blind , placebo-controlled , randomize , multicenter investigation rBV A/B-40 vaccine placebo healthy adult , use two different three-dose dosing schedule .</brief_summary>
	<brief_title>Double Blind , Safety Immunogenicity Study Recombinant Botulinum Vaccine A/B</brief_title>
	<detailed_description>The study include 18 month ( 547 day ) follow-up first vaccination randomize volunteer receive least one vaccination . Analysis cumulative data collect Day 547 ± 14 day report final clinical study report .</detailed_description>
	<mesh_term>Botulism</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . The volunteer sign informed consent form . 2 . The volunteer 18 55 year age . 3 . The volunteer agree donate blood blood product therapeutic research purpose . 4 . The volunteer willing comply requirement protocol . 5 . The volunteer clinically significant abnormality electrocardiogram . 6 . Female volunteer childbearing potential must pregnant lactate agree use two type acceptable form FDAapproved contraception Day 365 ± 7 day . 7 . The volunteer good health . 8 . The volunteer clinical laboratory test result within range list protocol . 1 . The volunteer history botulism prior receipt botulinum vaccine , toxoid antitoxin . 2 . The volunteer previously treat expect treat therapeutic product contain BoNTs Botox® , Myobloc®/Neurobloc™ Botox® Cosmetic . 3 . The volunteer history hypersensitivity significant adverse reaction vaccine , aluminum compound yeast . 4 . The volunteer donate one unit blood undergone plasmapheresis within past 28 day . 5 . The volunteer receive blood product immunoglobulin previous 6 month . 6 . The volunteer receive investigational vaccine previous 6 month . 7 . The volunteer receive licensed nonliving vaccine within 14 day schedule vaccination . 8 . The volunteer receive licensed live vaccine within 60 day schedule vaccination . 9 . The volunteer receive investigational drug therapy within 30 day first vaccination last scheduled visit . 10 . The volunteer receive therapy immunosuppressive agent , include use moderate highdose oral inhale systemic corticosteroid ( prednisoneequivalent dose ≥ 20 mg/day ) . 11 . The volunteer neurological condition associate spasticity abnormal muscle contraction , demyelination , abnormality smooth skeletal muscle function , migraine headache , hyperhidrosis . 12 . The volunteer systemic recurrent disease condition would place volunteer unacceptable risk injury require frequent continuous medical intervention treatment , require hospitalization , likely require surgical intervention course study . 13 . The volunteer history immunodeficiency autoimmune disease . 14 . The volunteer systemic medical condition ongoing require hospitalization administration antimicrobial agent within 6 month screen . 15 . The volunteer history arthritis one occasion relate trauma episode nontraumarelated arthritis within previous 6 month . 16 . The volunteer acute selflimited illness resolved time first vaccination include oral temperature great 99.5 °F . 17 . The volunteer history abuse alcohol drug within 12 month study screen . 18 . The volunteer occupational responsibility would prevent completion participation study . 19 . The volunteer body mass index ≥ 35 kg/m2 . 20 . The volunteer confirm positive result urine drug screen test common substance abuse amphetamine , barbiturate , benzodiazepine , cocaine , opiates cannabinoids . 21 . The volunteer seropositive screening test human immunodeficiency virus , hepatitis C virus hepatitis B surface antigen . 22 . The volunteer currently active duty U.S. military .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>